Lith-O-Asp, with the CAS number 881179-02-8, is a chemical compound that serves as a lithium salt of aspartic acid. It is primarily studied for its potential applications in the treatment of mood disorders, particularly bipolar disorder, due to the mood-stabilizing properties associated with lithium. The compound is characterized by its ability to influence neurotransmitter activity in the brain, which may contribute to its therapeutic effects. Lith-O-Asp is typically administered in a controlled dosage to minimize side effects commonly associated with lithium therapy, such as gastrointestinal disturbances and renal function alterations. Its solubility in water and stability under physiological conditions make it suitable for various formulations. As with any lithium-containing compound, monitoring of serum lithium levels is essential to avoid toxicity. Research into Lith-O-Asp continues to explore its efficacy and safety profile, as well as its potential benefits compared to traditional lithium therapies.

Lith-O-Asp

881179-02-8: Lith-O-Asp, with the CAS number 881179-02-8, is a chemical compound that serves as a lithium salt of aspartic acid. It is primarily studied for its potential applications in the treatment of mood disorders, particularly bipolar disorder, due to the mood-stabilizing properties associated with lithium. The compound is characterized by its ability to influence neurotransmitter activity in the brain, which may contribute to its therapeutic effects. Lith-O-Asp is typically administered in a controlled dosage to minimize side effects commonly associated with lithium therapy, such as gastrointestinal disturbances and renal function alterations. Its solubility in water and stability under physiological conditions make it suitable for various formulations. As with any lithium-containing compound, monitoring of serum lithium levels is essential to avoid toxicity. Research into Lith-O-Asp continues to explore its efficacy and safety profile, as well as its potential benefits compared to traditional lithium therapies.

<p>Lith-o-Asp is a glycan that inhibits the growth of cancer cells by binding to the extracellular domain of mammalian cell surface receptors. This binding blocks the interaction between the receptor and its ligand, which is necessary for tumor growth. Lith-o-Asp has been shown to inhibit angiogenic growth in pancreatic cancer cells and suppress tumor growth in vivo. It also binds to glycoconjugates on the surface of cancer cells and inhibits tumor progression.</p>

Lith-o-Asp

<p>Lith-O-Asp is a sialytransferase (ST) inhibitor,(IC50s:12-37 μM).</p>

CAS 881179-02-8

Lith-O-Asp

Lith-o-Asp

Ref: 3D-GKB17902

Lith-O-Asp

Ref: TM-T11858